전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-4 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved7 programs
CGTLimited DatastaleChulalongkorn UniversityPhase 1

B7H3 specific CAR T cell with IL-7Ra signaling domain (B7H3 specific CAR T cell with IL-7Ra signaling domain)

DIPG Brain Tumor; Diffuse Intrinsic Pontine Glioma · DIPG Brain Tumor

#DIPGBrainTumor#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 2Status Recruiting
CGTLimited DatastaleChulalongkorn UniversityPhase 1

CD19-IL7Ra CAR-T cells (CD19-IL7Ra CAR-T cells)

Relapse B Acute Lymphoblastic Leukemia; Refactory Childhood Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleHenan Hualong Biotechnology Com…Phase 1

CD19/CD20 bispecific CAR-T cells (CD19/CD20 bispecific CAR-T cells)

B-Cell Lymphoma Stage I; Refractory · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleShanghai Longyao Biotechnology …Phase 1

CD20 CAR-T (CD20 CAR-T)

Relapsed and Refractory B Cell Lymphoma; Non-Hodgkin Lymphoma · CD20

#CD20#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleShanghai Longyao Biotechnology …Phase 2

Mixed CD19/CD20 CAR-T Transfer (Mixed CD19/CD20 CAR-T Transfer)

Recurrent or Refractory B Cell Malignancy · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleThe Evan FoundationPhase 1

long spacer 2nd generation T cells (Patient Derived CD171 specific CAR T cells expressing EGFRt, Patient Derived CD171 specific CAR T cells expressing EGFRt (long spacer 2nd generation T cells))

Neuroblastoma; Ganglioneuroblastoma · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleNovartis PharmaceuticalsPhase 3

Previously treated CAR-T patients (Previously treated CAR-T patients)

Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program · Long Term Safety of Patients Receiving C

#LongTermSafetyofPatientsReceivin#CGT#Phase3#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting